Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GRI Bio, Inc. (GRI)

GRI Bio presents new Phase 2a biomarker data for GRI-0621 in idiopathic pulmonary fibrosis

Neutral Impact 3 of 5 other Written later

GRI Bio, Inc. issued a press release on September 8, 2026 presenting new translational biomarker data from its Phase 2a GRI-0621-IPF-02 study of oral tazarotene in idiopathic pulmonary fibrosis, and posted an updated corporate presentation. The filing reports that the 12-week, 35-patient study showed a placebo-adjusted FVC change of +99 mL overall, but the company states the study was not powered for efficacy and the FVC endpoint was exploratory, so the data do not establish clinical benefit.

Key points

  • Placebo-adjusted FVC change from baseline at Week 12 was +99 mL overall and +139 mL in the subset on background standard-of-care antifibrotic therapy.
  • The study enrolled 35 patients: 23 on GRI-0621 and 12 on placebo; the FVC endpoint was exploratory and the study was not powered for efficacy.
  • Data were presented at the 2026 European Respiratory Society Congress in Barcelona, Spain, and the company said totality of findings supports advancing GRI-0621 in the IPF program.
  • The filing was made under Items 7.01, 8.01 and 9.01 and includes Exhibits 99.1 (corporate presentation) and 99.2 (press release).

The filing

CompanyGRI Bio, Inc. (GRI)
Form8-K, current report
Filed with the SECSep 8, 2026, 8:16 AM ET
Accession number0001824293-26-000057

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.